The cost, which is confidential and was negotiated for all in all , 300 huge number of doses, is a little lower than the $19.50 a shot the United States agreed to purchase a very first shipment of hundred million doses of the identical vaccine, in series with what Reuters reported in November.
The EU file dated Nov. 18 was circulated internally following the EU announced the supply deal of its with Pfizer and the German partner BioNTech of its on Nov. 11.
The EU drug regulator is anticipated to decide on Monday on approval for the Pfizer vaccine following the shot was authorised in a few countries, including Britain and also the United States.
On Thursday Belgian state secretary for the spending budget Eva De Bleeker released on Twitter a dining room table with prices Belgium will pay pharmaceutical companies for their COVID 19 vaccines. She retracted the article shortly after publishing.
In that dinner table the Pfizer vaccine was suggested as costing Belgium twelve euros ($14.6) per dose, leading many to believe this was the total cost agreed with the EU.
Other vaccines in the family table were furthermore shown with prices lower than rates disclosed by EU solutions.
“There is , obviously , a total price and a price upon delivery,” an EU official involved in talks with vaccine makers told Reuters when asked to clarify the difference between the EU and Belgian prices.
A spokesman for De Bleeker declined to comment on Monday, citing confidentiality requirements, but pointed to what De Bleeker told the Belgian parliament last week. In that public hearing, De Beeker said Belgium’s budgeted prices were still partial.
Under EU advance purchase deals for COVID-19 vaccines, the bloc concurs upfront payments with business enterprises to secure doses before they’re approved. Following approvals, EU governments can pay the rest to buy reserved doses.
The EU has not revealed the initial transaction agreed with Pfizer.
But, it stated in October that it paid aproximatelly 1 billion euros in downpayments to AstraZeneca, Sanofi and Johnson & Johnson for their shots, with a further 1.45 billion euros budgeted for initial payments to Pfizer-BioNTech, Moderna and Curevac.
It’s since agreed supply deals with all 6 companies and is negotiating a seventh understanding with Novavax.